INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 414m ago
HOUSE PTR13m ago
SEC 13F13m ago
ROBINHOOD CHAIN13m ago
SEC FORM 4/Derivative conversionVerified data

Salvia Investment GmbH reported BBTX

10% Owner · Bambusa Therapeutics, Inc. · Common Stock

Side
C
Value
—
Shares
4.77M
Price
—
Executed
Nov 2, 2026
Disclosed
Nov 2, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 2, 2026 disclosed

BBTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+13 / 25

    No reported dollar value · 115.8% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BBTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SG
    Salvia Investment GmbH10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    1.47M sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    4,155 sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    10.4K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    1,753 sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    94.0K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    15.8K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JW
    Jeggle Helmut WolfgangDirector, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    3.14M sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JW
    Jeggle Helmut WolfgangDirector, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    1.47M sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JW
    Jeggle Helmut WolfgangDirector, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    160.9K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    37.4K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    16.4K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    43
    SG
    Salvia Investment GmbH10% Owner
    BBTXBambusa Therapeutics, Inc.
    Open-market purchase
    		BUY$6.00M
    375.0K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SG
    Salvia Investment GmbH10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    3.14M sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SG
    Salvia Investment GmbH10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    160.9K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    147.2K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Grant or award
    		A—
    379.1K sh
    		Oct 29, 2026Nov 2, 2026
    traded Oct 29, 2026
    		+4dSEC FORM 4

    Evidence

    9
    XS
    Xu ShanshanDirector, See remarks, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Grant or award
    		A—
    758.2K sh
    		Oct 29, 2026Nov 2, 2026
    traded Oct 29, 2026
    		+4dSEC FORM 4

    Evidence

    43
    JW
    Jeggle Helmut WolfgangDirector, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Open-market purchase
    		BUY$6.00M
    375.0K sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    JW
    Jeggle Helmut WolfgangDirector, 10% Owner
    BBTXBambusa Therapeutics, Inc.
    Derivative conversion
    		C—
    4.77M sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002162499-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 2, 2026
    Published
    Nov 2, 2026
    Ingested by INSIDER
    Nov 5, 02:08 UTC
    Last re-read
    Nov 5, 02:08 UTC

    Extracted facts

    Filer
    Salvia Investment GmbH
    Role
    10% Owner
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    Bambusa Therapeutics, Inc.
    Ticker
    BBTX
    Shares
    4.77M
    Execution date (reported)
    Nov 2, 2026
    Owned after transaction
    8.89M shares
    Days from execution to publication
    0

    What this establishes

    Salvia Investment GmbH filed this Form 4 reporting a derivative conversion of BBTX on Nov 2, 2026. It became public on Nov 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    10% Owner
    Salvia Investment GmbHcik:0002162499
    Issuer
    Bambusa Therapeutics, Inc.cik:0002044950

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.